导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.96% | 2936/4773 |
| 近一周 | -1.58% | 2322/5465 |
| 近一月 | -0.44% | 832/5421 |
| 近一季 | 0.51% | 903/5231 |
| 近半年 | -5.87% | 3113/4920 |
| 近一年 | -1.91% | 3006/4394 |
| 近两年 | 22.38% | 2602/2954 |
| 近三年 | 12.82% | 1686/2253 |
| 成立以来 | 81.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.25% 994/4961 |
-10.42% 4104/5312 |
- - |
- - |
| 2025 | 2.71% 3169/4813 |
-2.47% 2894/3635 |
2.06% 1906/4076 |
1.83% 3862/4524 |
1.34% 1415/4813 |
| 2024 | 16.21% 833/3463 |
3.28% 603/2808 |
0.28% 636/3014 |
10.90% 2579/3129 |
1.18% 1107/3463 |
| 2023 | 12.62% 57/2656 |
8.58% 453/2280 |
3.15% 104/2385 |
3.68% 175/2515 |
-3.01% 577/2655 |
| 2022 | 1.65% 30/2207 |
3.99% 41/1919 |
-1.90% 1759/2016 |
-4.83% 65/2113 |
4.71% 516/2208 |
| 2021 | 22.30% 149/1822 |
8.98% 58/1255 |
1.45% 1051/1330 |
6.97% 202/1466 |
3.40% 439/1822 |
| 2020 | 4.09% 910/1250 |
-11.36% 838/1028 |
5.41% 881/1067 |
8.50% 710/1164 |
2.67% 975/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 天弘中证红利低波动100联接C VS. 长安沪深300非周期A(740101) |